Future Fund LLC Buys Shares of 21,730 Guardant Health, Inc. $GH

Future Fund LLC purchased a new position in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 21,730 shares of the company’s stock, valued at approximately $1,131,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in GH. Signaturefd LLC lifted its stake in Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock valued at $4,439,000 after buying an additional 282 shares in the last quarter. IFP Advisors Inc lifted its position in Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after buying an additional 334 shares during the last quarter. HighTower Advisors LLC boosted its stake in Guardant Health by 0.9% in the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock worth $2,177,000 after buying an additional 469 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in Guardant Health by 25.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock worth $112,000 after buying an additional 537 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Buying and Selling

In other Guardant Health news, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares of the company’s stock, valued at approximately $126,242,015.55. The trade was a 12.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the firm’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the sale, the director directly owned 851 shares of the company’s stock, valued at approximately $46,090.16. This represents a 71.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 302,691 shares of company stock valued at $17,984,628. 6.10% of the stock is owned by corporate insiders.

Guardant Health Price Performance

NASDAQ GH opened at $96.72 on Friday. Guardant Health, Inc. has a 1 year low of $28.20 and a 1 year high of $100.22. The stock has a market capitalization of $12.19 billion, a PE ratio of -30.13 and a beta of 1.56. The business’s 50-day moving average is $67.52 and its 200 day moving average is $55.05.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.26). The business had revenue of $265.20 million during the quarter, compared to analyst estimates of $235.72 million. During the same period last year, the firm earned ($0.88) earnings per share. Guardant Health’s revenue was up 38.5% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have commented on the stock. Evercore ISI lifted their price target on shares of Guardant Health from $68.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Raymond James Financial lifted their target price on shares of Guardant Health from $59.00 to $61.00 and gave the stock an “outperform” rating in a research report on Thursday, July 31st. UBS Group boosted their price target on shares of Guardant Health from $80.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Thursday, September 25th. Finally, Wolfe Research upgraded Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price objective on the stock in a report on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $77.14.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.